Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRI-0621 in Patients With Chronic Liver Disease
NCT02949375Phase 2Terminated
- Sponsor
- GRI Bio, Inc.
- Start
- Sep 2015
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GRI-0621 in chronic liver disease (CLD), sponsored by GRI Bio, Inc. Primary endpoint: Change in serum alanine transaminase levels at Day 28. Started Sep 2015; status: terminated.
02
Drugs
GRI-0621
03
Conditions
chronic liver disease (CLD)
Beyond the preview
Go deeper on NCT02949375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02949375.